A niacin-cholic acid-peptide conjugate disrupts bacterial membranes, allowing erythromycin to kill Gram-negative bacteria and eliminate polymicrobial biofilms.
Erythromycin repurposedNormally ineffective against Gram-negative bacteria, erythromycin became bactericidal when combined with the peptide conjugate
What the researchers found
The niacin-cholic acid-peptide conjugate (amphiphile 1) acts as a membrane disruptor for Gram-negative bacteria, creating entry points for erythromycin. The combination was bactericidal against Gram-negative pathogens, eliminated monomicrobial and polymicrobial biofilms, and showed antibacterial effectiveness in wound infection models. This approach repurposes an existing antibiotic for infections it normally cannot treat.
Why it matters
Antibiotic resistance, especially in Gram-negative bacteria, is a global health crisis. Rather than developing entirely new antibiotics, this approach uses a peptide conjugate to make existing antibiotics work against bacteria they couldn't previously kill — a faster and cheaper path to new treatments.
The numbers in context
Not specified — proof-of-concept study with the peptide conjugate designated as compound 1.
How the study worked
Peptide conjugate design and synthesis, followed by in vitro testing against Gram-negative bacteria. Assessed membrane disruption, bactericidal activity, and biofilm elimination. Tested in monomicrobial and polymicrobial wound infection models.
Who was studied
In vitro testing against Gram-negative bacterial pathogens
What this study cannot tell us
Primarily in vitro and wound model data — no systemic in vivo pharmacokinetics or toxicity data. Unclear whether the conjugate would be stable and effective in human wound environments. Only tested with erythromycin; other antibiotic combinations not explored. Long-term resistance development not assessed.
How to read the evidence
Rated preliminary: proof-of-concept study with in vitro and wound model data. No clinical trial or systemic pharmacokinetic data.
When this study was published
Published in 2024. Represents the growing field of peptide-drug conjugates for antibiotic resistance.
The bigger picture
Peptide-drug conjugates represent a growing strategy for combating antibiotic resistance. By using peptides to disrupt bacterial membranes, previously ineffective antibiotics can be revitalized — potentially extending the useful life of our existing antibiotic arsenal.
Questions still open
- Would this conjugate work with other antibiotics besides erythromycin?
- Could bacteria develop resistance to this membrane disruption strategy?
- What is the safety profile of the peptide conjugate in human wound tissue?
Common questions
Can peptides help fight antibiotic resistance?
What are peptide-drug conjugates?
Read the original research
Niacin-Cholic Acid-Peptide Conjugate Act as a Potential Antibiotic Adjuvant to Mitigate Polymicrobial Infections Caused by Gram-Negative Pathogens.
ACS infectious diseases, 10(12), 4146-4155
Citation
Safwan, Sayed M; Mehta, Devashish; Arora, Amit; Khatol, Steffi; Singh, Mohit; Rana, Kajal; Gupta, Sonu K; Kumar, Yashwant; Verma, Vikas; Saini, Varsha; Bajaj, Avinash. (2024). Niacin-Cholic Acid-Peptide Conjugate Act as a Potential Antibiotic Adjuvant to Mitigate Polymicrobial Infections Caused by Gram-Negative Pathogens.. ACS infectious diseases, 10(12), 4146-4155. https://doi.org/10.1021/acsinfecdis.4c00404